WuXi Biologics expands manufacturing to Singapore with $60m facility
WuXi Biologics is expanding its manufacturing site network to Singapore with the construction of a $60m facility for clinical and small volume commercial production.
Top Headlines
Global Industry News
-
Excipient makers want to be the ‘first second’ in novel ingredient development, say execs
from in-PharmaTechnologist.com
-
BioCity-backed CROs target biotech, mid-sized pharma customers in new discovery alliance
from Outsourcing-Pharma.com
-
CDMO Tedor Pharma recapitalizes following multi-million dollar investment
from Outsourcing-Pharma.com
-
Motif Bio secures £10m to support antibiotic commercialization efforts
from in-PharmaTechnologist.com
Hot Topics
-
GE boosts powdered cell culture media capacity in ‘mature’ markets
Cell & Gene Therapies
-
Experts warn: If Europe doesn’t innovate, it will lose manufacturing to pharmerging countries
Emerging Markets
-
Pfizer collects its third US FDA biosimilar approval with Retacrit
Biosimilars
-
Oncology candidate returns to Lilly with $110m AurKa Pharma buy
Cell & Gene Therapies
